Featured Listing

AlphaMaven

Company Logo'

Venture Capital Featured Listing

BrookDell Partners

Back

Venture Capital

Andrea Alms Video: Money In Motion 28 - The Obesity Tech Market

October 2022 - Venture Capital

posted by BrookDell Partners

TRANSCRIPT:


Hello. My name is Andrea Alms. I am technology investor and financial manager and this is your money in motion. The global obesity treatment market is valued at 5 billion in 2018 and is estimated to reach 14 billion by 2026 at a compound average growth rate of 12%. The U.S. obesity treatment market is estimated to grow to 3 billion in 2021 and projected to grow at a compound average growth rate of 9% to reach 5 billion by 2027. Obesity can be denoted as a condition where excess fat accumulates, is seen in the body and leads to associated health risks such as cardiovascular diseases, diabetes, SE orthopedic disorder. Previously, it was thought obesity was prevalent only in high income countries. However, this has drastically changed in recent times where the rate of obesity is increasing even in middle and low income countries. It is also a fact that more than 30% of the world's population is either overweight or obese. Yes, a $1,000,000,000 market and only single digit growth rate in the U.S.. Where can we find that higher double digit growth rate? As for the market segment, there are drugs, surgery, fitness equipment and dietary supplements. What about software and tech? In the drug segment, we find the usual suspects in key players Lilly, Pfizer and so on. In a previous episode. The drug market is $100 billion market with single digit growth, extremely concentrated market with few players. Of course, in the weight loss equipment market. The key players are Olympus, Covidien and so on. This segment is double digit billion dollar market with a single digit growth rate. Finally, our software and tech app. Here are some of the leading fitness and weight loss apps Fitbit, Fat Secret and so on. The Global Fitness app market is valued at about 13 billion in 2020 and is projected to reach over 120 billion by 2030 at a compound average growth rate of 24%. Yes, this is our sweep spot, a multibillion dollar market and relatively double digit high growth rate. Thank you. This is your money. Your money in motion.


ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.
ALL ALPHAMAVEN CONTENT IS FOR INFORMATIONAL PURPOSES ONLY. CONTENT POSTED BY MEMBERS DOES NOT NECESSARILY REFLECT THE OPINION OR BELIEFS OF ALPHAMAVEN AND HAS NOT ALWAYS BEEN INDEPENDENTLY VERIFIED BY ALPHAMAVEN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. THIS IS NOT A SOLICITATION FOR INVESTMENT. THE MATERIAL PROVIDED HEREIN IS FOR INFORMATIONAL PURPOSES ONLY. IT DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY INTERESTS OF ANY FUND OR ANY OTHER SECURITIES. ANY SUCH OFFERINGS CAN BE MADE ONLY IN ACCORDANCE WITH THE TERMS AND CONDITIONS SET FORTH IN THE INVESTMENT'S PRIVATE PLACEMENT MEMORANDUM. PRIOR TO INVESTING, INVESTORS ARE STRONGLY URGED TO REVIEW CAREFULLY THE PRIVATE PLACEMENT MEMORANDUM (INCLUDING THE RISK FACTORS DESCRIBED THEREIN), THE LIMITED PARTNERSHIP AGREEMENT AND THE SUBSCRIPTION DOCUMENTS, TO ASK SUCH QUESTIONS OF THE INVESTMENT MANAGER AS THEY DEEM APPROPRIATE, AND TO DISCUSS ANY PROSPECTIVE INVESTMENT IN THE FUND WITH THEIR LEGAL AND TAX ADVISERS IN ORDER TO MAKE AN INDEPENDENT DETERMINATION OF THE SUITABILITY AND CONSEQUENCES OF AN INVESTMENT.